50% of non-small cell lung cancer, renal cell carcinoma, and melanoma patients experienced partial remission within the first 2 months of treatment with Nivolumab.
UNCOMMONsideeffects
severe immune-mediated side effects involving healthy organs including: lung, colon,
liver kidneys, hormone-producing glands
Nivolumab
(Lung Cancer, Laryngeal Cancer, Kidney Cancer)
Nivolumab is administered intravenously over the course of 60 minutes every 2 or 3 weeks.
COMMONsideeffects
joint, back,
jaw, or bone pain,
muscle pain or weakness, dry,
cracked, scaly skin,
mouth sores, dry eyes or mouth,
skin, hair,
or eye discoloration
Do you want to show doctors in your area?
We are sorry but your curent location dosen't have a postal code atached. We cannot display doctors in your area.
